Board

Christian Kinch founded SmartCella together with Thomas von Koch and Professor Kenneth Chen in 2014 and is one of the main shareholders. Christian is the former CEO of Bactiguard and is a serial entrepreneur within pharmaceuticals and medtech and has previously founded Netpharma AB and Kinchard AB. He is a Board Member of Swecare Aktiebolag and owner and Director of the Board of KK Consult AB and KK Invest AB. Christian holds an MSc in Economics from Stockholm School of Economics.

Magnus Tornling joined EQT Partners in Oslo in 2016 and is a Partner and Global Head of Equity Capital Markets at private equity firm EQT. Prior to joining EQT, Magnus spent twelve years in the Corporate Finance department of ABG Sundal Collier in Oslo, lastly as the Co-Head of Investment Banking and Head of Equity Capital Markets. Magnus holds an MSc in finance from the Norwegian School of Management.

Claude Dartiguelongue is an experienced top-level executive with a distinguished career in blue-chip companies across the Healthcare and Life Sciences industry. She is the former President of the Capsules and Health Ingredients division at Lonza where she was a member of the Executive Committee. She also led global business units at Thermo Fischer Scientific (Microbiology Division) and Becton Dickinson (BD Pharmaceutical Systems and BD Biosciences). Claude holds an MSc in Medical Management from ESCP Business School and an MSc in Biotechnology from the University of Grenoble

Anna Martling is a globally recognized and awarded scientist and surgeon with a focus on oncology. She is Professor of surgery and the former Dean at Karolinska Institutet where she currently serves as the Scientific Director Life Science. Additionally, Anna chaired The Task Force for Precision Medicine at Karolinska Institutet/Region Stockholm. She holds an MD and PhD in Surgery from Karolinska Institutet, with her thesis specializing in rectal cancer.

Dr Regina Fritsche-Danielson is Senior Vice President and Globaland Head of Research and Early Development, Cardiovascular, Renal and Metabolic Diseases. She is responsible for Metabolism, Biopharmaceuticals at AstraZeneca R&D with accountability for global research and early clinical development up to Ph3 in cardiovascular, renal and metabolic diseases. Regina has a broad scientific background in human and animal physiology and received her PhD in Cardiovascular Physiology/Pharmacology at the University of Göteborg in 1993. After her postdoc, Regina was awarded a prestigious grant from the Swedish Natural Research Foundation (NFR) and lead a research group working at the University of Göteborg, University of Ottawa, University of Queensland and University of Nevada. Regina joined AstraZeneca in 2001 and has held various leadership positions and she has delivered several candidate drugs many of which has progressed into late-stage development.